Breakthrough Blood Test for Early Detection of Brain Tumors

A groundbreaking blood test has been developed that can detect brain tumors with over 90% accuracy, offering a non-invasive alternative to traditional diagnostic methods. This innovative approach focuses on identifying specific proteins in the blood, allowing for earlier detection and better monitoring of treatment responses. Researchers from the University of Manchester, in collaboration with teams in Denmark, aim to streamline the complex process of brain tumor diagnosis. If validated through larger clinical trials, this test could significantly improve survival rates and treatment outcomes, marking a significant advancement in cancer care. The potential for routine blood tests to play a crucial role in cancer screening is on the horizon, promising a future where early detection becomes the norm.

By Narendra Chaudhary Mar 17, 2026, 08:07 IST

Innovative Blood Test for Brain Tumor Detection

Researchers have made significant strides in developing a blood test capable of identifying brain tumors and monitoring them in real-time. This test boasts an impressive accuracy rate exceeding 90%, potentially aiding physicians in detecting malignant growths. Initial studies have concentrated on aggressive glioblastomas, with plans to extend the research to various other brain tumor types. Currently, managing brain tumors is not only complex but also challenging in advanced stages, often necessitating numerous MRI scans and invasive biopsies. However, a team from the University of Manchester, in collaboration with Danish researchers, believes this process can be greatly simplified.

Mechanism of the Blood Test

The scientists discovered two specific proteins in the bloodstream that can accurately identify tumors and provide insights into their response to treatments. These proteins, known as liquid biopsy markers, enable doctors to detect tumors without needing direct access to brain tissue. The test can differentiate between tumor-related signals and normal biological functions, achieving over 90% accuracy in preliminary trials. This advancement could lead to:

Earlier tumor detection compared to conventional imaging methods
A reduction in the necessity for invasive diagnostic techniques
Enhanced monitoring of tumor development and treatment efficacy

Lead researcher Prof. Petra Hamerlik stated, “Glioblastoma is one of the most challenging cancers we encounter. The absence of reliable testing has hindered early diagnosis and monitoring of treatment responses.” The goal is to create a device similar to a COVID-19 test. Once validated, it will be submitted for regulatory approval and, hopefully, integrated into the NHS within the next decade.

Distinctive Features of the Test

In contrast to traditional diagnostic methods, this blood test provides a non-invasive and scalable alternative. Patients may only require a standard blood sample, facilitating its incorporation into regular health assessments. Medical professionals believe this could be especially advantageous in areas with limited access to advanced imaging technologies, enabling broader and earlier screening for brain cancers. Currently, a clinical trial is underway at six sites in the UK and four internationally.

Potential Impact on Cancer Treatment

Experts assert that if validated through extensive clinical trials, this innovation could greatly enhance survival rates and treatment outcomes. Early detection allows for prompt treatment initiation, often when tumors are smaller and more manageable. The test may also assist in:

Rapid identification of tumor types
Personalizing treatment strategies
Monitoring the effectiveness of therapies over time

This aligns with the increasing trend towards precision medicine, where treatments are customized based on individual biological markers. The advancement of this blood test signifies a broader movement in oncology towards minimally invasive diagnostic tools. Similar methodologies are being investigated for other cancers, including lung, breast, and colorectal cancers. Experts believe such innovations could pave the way for a future where routine blood tests are integral to cancer screening, facilitating early disease detection before symptoms manifest.